+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.

Age: 35Years - 50YearsFEMALEPhase Not Applicable
574 locations
P

Actively Recruiting

Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.

All AgesAll GendersPhase 3
629 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
A

Actively Recruiting

Researchers are evaluating the use of NuShield4, a dehydrated placental allograft, combined with standard care compared to standard care alone for treating non-healing venous leg ulcers VLUs. This prospective, multi-center, randomized controlled trial aims to gather outcome data on wound healing effectiveness in adults with VLUs. The study is sponsored by Organogenesis and focuses on ulcers that have not healed with conventional treatment. Participants will be randomly assigned to receive either NuShield4 plus standard care or standard care alone. Standard care includes standard compression therapy and wound management. The study measures include the proportion of subjects achieving complete wound closure by 16 weeks, with secondary outcomes assessing closure by 12 weeks, time to closure, and percentage reduction in wound area. Weekly study visits will support treatment and monitoring. During the trial, participants will attend weekly visits for wound assessment and treatment. Researchers will evaluate wound healing progress using clinical evaluations and document outcomes like total wound closure and wound size reduction. The study requires participants to comply with all visits and procedures, including informed consent and contraception use for those of childbearing potential. The total duration for primary outcome assessment is 16 weeks, with safety and compliance monitored throughout.

Age: 18Years +All GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the use of Electroencephalogram EEG based Transcranial Magnetic Stimulation eTMS to treat Post-Traumatic Stress Disorder PTSD in military veterans and first responders. This randomized, sham-controlled study aims to assess the safety and effectiveness of personalized eTMS treatment in reducing PTSD symptoms. The study is recruiting 110 participants aged 22 to 65 years with diagnosed PTSD lasting at least six months and meeting specific symptom severity criteria. Participants will undergo an EEG recording first to customize the eTMS treatment parameters. The treatment phase consists of 15 in-office visits over 21 to 28 days. Each visit includes two 15-minute eTMS sessions delivered at 80% motor threshold with pulse frequencies between 8 and 13 Hz. Sessions include 5-second pulse trains followed by 20-second intervals, with a rest of at least 30 minutes between the two daily sessions. A sham treatment arm follows the same schedule but with no actual magnetic stimulation. Throughout the study, participants will be assessed for changes in PTSD symptoms using the PTSD Checklist for DSM-5 PCL-5 from baseline to the end of treatment. Safety will also be monitored by recording any adverse events during the treatment period. The total study duration from first participant enrollment to last treatment is about 10 months, and participants will complete all visits and assessments within the treatment window of 21 to 28 days.

Age: 22Years - 65YearsAll GendersPhase Not Applicable
2 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
C

Actively Recruiting

Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.

Age: 18Years +All GendersPhase 3
846 locations
T

Actively Recruiting

Researchers are evaluating targeted cancer treatments directed by genetic testing for patients with locally advanced or advanced solid tumors. This ComboMATCH patient screening trial is designed to match patients with specific genetic mutations in their tumor cells to investigational combination therapies. Patients included have tumors that have spread or progressed after standard treatments, or have no standard treatment proven to extend survival. The study aims to improve treatment planning by using genetic information to assign therapies. Participants undergo tumor mutational screening using previously collected tumor samples. Eligible patients aged 18 and older with biopsiable disease may have a new biopsy before starting treatment. Those with relevant mutations are assigned to one of 20 treatment subprotocols involving various drug combinations and regimens, including oral, intravenous, and intramuscular administration. Treatments are given in repeated 28-day cycles, continuing without disease progression or unacceptable toxicity. The trial includes multiple arms and cohorts tailored to specific genetic alterations and cancer types, with some allowing crossover if disease progresses. Throughout the study, participants have tumor biopsies, blood collections, imaging tests such as CT, MRI, PET scans, and cardiac assessments like echocardiograms or MUGA scans. Bone marrow aspirations or biopsies, bone scans, and brain imaging may also be performed as clinically indicated. Researchers measure patient enrollment and treatment assignment, as well as positive treatment outcomes in defined molecular cohorts. The trial may last up to 8 years, with ongoing monitoring and optional additional biopsies at disease progression to assess treatment effects and safety.

All AgesAll GendersPhase 2
484 locations

1-10 of 17

1